Scarica l'app Stockscreener
13.89
1.42%
-0.20
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DNLI Giù?
Forum
Previsione
Denali Therapeutics Inc Borsa (DNLI) Ultime notizie
(DNLI) Investment Analysis - news.stocktradersdaily.com
Transcript : Denali Therapeutics Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-10-2025 01 - MarketScreener
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Ameriprise Financial Inc. Has $341,000 Stock Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
15,100 Shares in Denali Therapeutics Inc. (NASDAQ:DNLI) Acquired by Two Sigma Advisers LP - Defense World
Why Is Denali Therapeutics (DNLI) Up 0.7% Since Last Earnings Report? - Yahoo Finance
Denali Therapeutics Enters Registration Rights Agreement - TipRanks
(DNLI) On The My Stocks Page - news.stocktradersdaily.com
Q2 EPS Estimate for Denali Therapeutics Boosted by Analyst - Defense World
Nuveen Asset Management LLC Sells 360,243 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Stifel maintains Buy on Denali Therapeutics stock, $37 target - Investing.com Australia
Stifel Nicolaus Reaffirms Their Buy Rating on Denali Therapeutics (DNLI) - The Globe and Mail
Bank of America Corp DE Trims Stock Position in Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Stifel maintains Buy on Denali Therapeutics stock, $37 target By Investing.com - Investing.com UK
BNP Paribas Financial Markets Sells 11,682 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
Sanfilippo syndrome Pipeline 2025: Groundbreaking Clinical - openPR.com
Millennium Management LLC Acquires 344,056 Shares of Denali Therapeutics Inc. (NASDAQ:DNLI) - Defense World
When (DNLI) Moves Investors should Listen - news.stocktradersdaily.com
Hunter Syndrome Pipeline Appears Robust With 10+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - The Globe and Mail
Metachromatic Leukodystrophy Pipeline 2025: Groundbreaking - openPR.com
Denali Therapeutics (DNLI) Receives a Price Target Adjustment fr - GuruFocus
Denali Therapeutics (DNLI) Receives a Price Target Adjustment from B of A Securities | DNLI Stock News - GuruFocus
Denali Therapeutics (DNLI) Target Price Adjusted by Analyst | DN - GuruFocus
Denali Therapeutics Inc. (NASDAQ:DNLI) Receives Average Recommendation of “Buy” from Analysts - Defense World
Denali Therapeutics shares fall after price target cut to $32 By Investing.com - Investing.com Nigeria
HC Wainwright Issues Optimistic Estimate for DNLI Earnings - Defense World
Where are the Opportunities in (DNLI) - news.stocktradersdaily.com
Q1 Earnings Forecast for DNLI Issued By Wedbush - Defense World
Denali Q1 Loss Wider Than Expected, Hunter Syndrome Drug in Focus - MSN
Hunter Syndrome Treatment Market Expands with Enzyme - openPR.com
Denali Therapeutics (DNLI) Price Target Reduced to $30 by Analys - GuruFocus
Denali Therapeutics shares fall after price target cut to $32 - Investing.com
Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance
Denali Therapeutics (DNLI) Price Target Revised Amid Strategic D - GuruFocus
Denali Therapeutics Advances Pipeline Amid Financial Loss - TipRanks
Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwrigh - GuruFocus
Denali Therapeutics (DNLI) Target Price Adjusted by HC Wainwright & Co. | DNLI Stock News - GuruFocus
Denali Therapeutics (DNLI) Price Target Revised Amid Strategic Developments | DNLI Stock News - GuruFocus
Denali Therapeutics price target lowered to $32 from $80 at H.C. Wainwright - TipRanks
Decoding Denali Therapeutics Inc (DNLI): A Strategic SWOT Insigh - GuruFocus
Denali Therapeutics Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Denali Therapeutics Reports First Quarter 2025 Financial - GlobeNewswire
Breakthrough Hunter Syndrome Drug Heads to FDA: Denali's Brain-Barrier Treatment Could Transform Patient Care - Stock Titan
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates - TradingView
Biogen (BIIB) Completes Enrollment for Parkinson's Treatment Stu - GuruFocus
First Week of December 19th Options Trading For Denali Therapeutics (DNLI) - Nasdaq
(DNLI) Technical Data - news.stocktradersdaily.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA - openPR.com
Amyotrophic Lateral Sclerosis Pipeline 2025: MOA and ROA Insights, Clinical Trials, and Key Companies Involved by DelveInsight | Biogen, GSK, Helixmith, Sanofi, Denali Therapeutics, Ionis Pharma - The Globe and Mail
Denali Announces Rolling Regulatory Submission of Tividenofusp Alfa for Hunter Syndrome - Neurology live
Denali Therapeutics stock hits 52-week low at $12.05 - Investing.com Australia
Denali Therapeutics stock hits 52-week low at $12.05 By Investing.com - Investing.com Canada
1.86%
1.98%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):